Current Front-Line Targeted Treatments in Ph+ ALL

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

EP: 1.Overview of Characteristics Unique to Ph+ ALL

EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL

EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP: 4.Screening and Diagnosing of Ph+ ALL in Adults

EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

Now Viewing

EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL

EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care

EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

EP: 11.Disparities in Access to Care for Ph+ ALL patients

EP: 12.The Future of Ph+ ALL Treatments

EP: 13.Concluding Thoughts on Ph+ ALL Treatment

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!